Gynecological Cancers—Surgical Management, Prognosis, and Quality of Life

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Obstetrics & Gynecology".

Deadline for manuscript submissions: 25 March 2024 | Viewed by 1595

Special Issue Editor

Academic Division of Obstetrics and Gynecology, Mauriziano Umberto 1st Hospital, School of Medicine, University of Torino, 10128 Torino, Italy
Interests: breast cancer surgery and treatment; menopause; menopause after cancer

Special Issue Information

Dear Colleagues,

We are pleased to invite you to submit a paper for the Special issue “Gynecological Cancers—Surgical Management, Prognosis, and Quality of Life”. Works focusing on the treatment of endometrial, cervical, ovarian, vulvar, and vaginal and breast cancers also on survivorship after them are welcome.

The Special Issue will focus on the new findings in this area of expertise and will cover all the aspects of the path that women have to face. As regards treatment, the Special issue will accept original articles or review on surgical treatment, radiotherapy, and systemic treatment for primary or recurrent disease.

Thanks to the progress in treatment for many gynecological cancers in the last few years, quality of life of patients has become an important issue for clinicians. In particular, papers focusing on the side effects of treatment, such as lymphedema, or on menopausal symptoms treatment in this subset of patients or on the important topic of fertility preservation for gynecological oncological patients are also invited.

Furthermore, we strongly believe that a 360° consideration of patient may lead to an improvement in the adherence to therapy and that the future of gynecological oncology might also look in this direction. We look forward to your contribution.

Dr. Valentina Elisabetta Bounous
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • gynecological cancers
  • endometrial cancer
  • ovarian cancer
  • cervical cancer
  • vulvar cancer
  • vaginal cancer
  • breast cancer
  • surgery
  • radio-therapy
  • systemic treatment
  • quality of life

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


9 pages, 1730 KiB  
Case Report
A Rare Case of Hepatocellular Carcinoma Recurrence in Ovarian Site after 12 Years Mimicking a Hepatoid Adenocarcinoma: Case Report
J. Clin. Med. 2023, 12(7), 2468; - 24 Mar 2023
Viewed by 1295
Hepatoid carcinoma of the ovary (HCO) is a tumor that resembles, both histologically and cytologically, hepatocarcinoma (HCC) in a patient with a non-cirrhotic liver not involved by the disease. Hepatoid carcinoma is an extremely rare histologic subtype of ovarian cancer and should be [...] Read more.
Hepatoid carcinoma of the ovary (HCO) is a tumor that resembles, both histologically and cytologically, hepatocarcinoma (HCC) in a patient with a non-cirrhotic liver not involved by the disease. Hepatoid carcinoma is an extremely rare histologic subtype of ovarian cancer and should be distinguished from metastatic HCC. Here, we report the rare case of a 67-year-old woman with ovarian recurrence of HCC 12 years after first diagnosis. The patient was being followed by oncologists because she had been diagnosed with HCV-related HCC (Edmonson and Stainer grade 2, pT2 N0 M0, G2, V1) in 2009. She had undergone surgery for enlarged left hepatectomy to the 4th hepatic segment with cholecystectomy and subsequent placement of a Kehr drain. The preoperative alpha-fetoprotein (AFP) level was 8600 ng/mL, while the postoperative value was only 2.7 ng/mL. At the first diagnosis, no other localizations of the disease, including the genital tract, were found. At the time of recurrence, however, the patient was completely asymptomatic: her liver function was within normal limits with negative blood indices, except for an increased blood dosage of AFP (467 ng/mL), and CA125, which became borderline (37.4 IU/mL). The oncologist placed an indication for a thoracic abdominal CT scan, which showed that the residual liver was free of disease, and the presence of a formation with a solid–cystic appearance and some calcifications at the left adnexal site. The radiological findings were confirmed on level II gynecological ultrasound. The patient then underwent a radical surgery of hysterectomy, bilateral oophorectomy, pelvic peritonectomy, and omentectomy by a laparotomic approach, with the sending of intraoperative extemporaneous histological examination on the annexus site of the tumor mass, obtaining RT = 0. Currently, the patient continues her gyneco-oncology follow-up simultaneously clinically, in laboratory, and instrumentally every 4 months. Our study currently represents the longest elapsed time interval between first diagnosis and disease recurrence, as evidenced by current data in the literature. This was a rather unique and difficult clinical case because of the rarity of the disease, the lack of scientific evidence, and the difficulty in differentiating the primary hepatoid phenotype of the ovary from an ovarian metastasis of HCC. Several multidisciplinary meetings for proper interpretation of clinical and anamnestic data, with the aid of immunohistochemistry (IHC) on histological slides were essential for case management. Full article
Show Figures

Figure 1

Back to TopTop